Yesterday's news seems to indicate that CRMD has a plan. Hopefully they move up a tranche in the next financing round. A good hedge fund could bring more than $$$$$ to the table.
This will be all about execution. Beyond the Tauropharm issue CRMD will need to convince German(Euro) healthcare system of cost/benefit advantage of moving from older catheter lock products to Neutrolin. The good news is tthat the Europeans tend to look at total cost of care so infection prevention will be a major plus.
IP issue is the wildcard. Any settlement or eventual legal victory changes the timeline here re: robust sales dramatically.
Silly people to be selling now. Likely private placement buyers from the Fall being encouraged by their brokers (ooops, I meant financial advisers) to flip the proceeds into the next "great deal". When will customers learn that brokers earn on activity but fortunes come from patience.